Please assess the completion status of the following clinical trial:

Trial Title: Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic kidney disease with estimated GFR of 30 mL/minute or more.~* Patients receiving stable dose of ACE inhibitor or Angiotensin receptor blockers for at least one month.~* Patients not currently hypertensive more than 180/110 mmHg by clinic blood pressure.~* Hemoglobulin A1C\< 11%~Exclusion Criteria:~* Patients taking vitamin D analogs~* Calcium\> 10 mg/dL~* Phosphorus\>6 mg/dL~* Patients with anticipated need of dialysis in the next 6 weeks~* Patients unstable in the opinion of the investigator~* Patients who have emergent need for starting IV iron~* Patients who will be started on statins within the next 6 weeks~* Patients currently taking PDE5 inhibitors~* Patients allergic to radiocontrast, Zemplar or who can not take nitroglycerin~* Patients known to be HIV positive~* Patients who can not give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 mcg paricalcitol
- 2 (Type: ACTIVE_COMPARATOR): 2 mcg paricalcitol
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).